CSL Behring Gets Indication For Acquired Factor XIII Deficiency For Fibrogammin P In Japan
This article was originally published in PharmAsia News
Executive Summary
CSL Behring on Sept. 13 obtained approval in Japan for the use of plasma derivative Fibrogammin P, the purified concentrate of blood coagulation factor XIII, for the treatment of bleeding caused by acquired factor XIII deficiency.